Cite
HARVARD Citation
Perez, C. et al. (n.d.). 256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699). Journal for immunotherapy of cancer. p. A155. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Perez, C. et al. (n.d.). 256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699). Journal for immunotherapy of cancer. p. A155. [Online].